Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating Expenses        
Research and development $ 1,158,757 $ 56,459 $ 2,269,269 $ 165,997
Research and development - related party 33,333 72,527 83,333 375,151
Selling, general and administrative 244,609 359,660 985,037 1,031,517
Total Operating Expenses 1,436,699 488,646 3,337,639 1,572,665
Loss From Operations (1,436,699) (488,646) (3,337,639) (1,572,665)
Other (Expense) Income:        
Interest expense (26,418) (30,923) (159,202) (124,774)
Interest expense - related parties (683) (756) (1,977) (49,244)
Amortization of debt discount (3,566) 10,095 (201,455)
Amortization of debt discount - related parties (28,356)
Change in fair value of derivative liabilities 33,500 115,500 118,500 390,400
Warrant modification expense (54,100) (283,500)
Loss on exchange of notes payable for Series A Convertible Preferred Stock (262,470)
Loss on extinguishment of debt (1,504)
Gain on forgiveness of accrued expenses 38,427
Total Other (Expense) Income (51,267) 83,821 (561,821) 14,927
Net Loss (1,487,966) (404,825) (3,899,460) (1,557,738)
Dividend attributable to Series A preferred stockholders (197,911) (110,666) (534,919) (327,626)
Net Loss Applicable to Common Stockholders $ (1,685,877) $ (515,491) $ (4,434,379) $ (1,885,364)
Net Loss Per Common Share - Basic and Diluted $ (0.06) $ (0.02) $ (0.16) $ (0.07)
Weighted Average Common Shares Outstanding - Basic and Diluted 28,523,306 27,580,598 28,262,759 27,456,267